Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe
Sandoz announced the Committee for Medicinal Products for Human Use has adopted positive opinions, separately recommending the approval of both Sandoz' biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines. April 21, 2017